AVDL NASDAQ
Avadel Pharmaceuticals plc
1W: +0.1%
1M: +0.6%
3M: +43.7%
1Y: +104.5%
3Y: +208.7%
5Y: +207.4%
$21.64
Last traded 2025-12-31 — delisted
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$2.1B
52W Range6.38-23.57
Volume35,016,239
Avg Volume2,415,222
Beta1.31
Dividend—
Analyst Ratings
Company Info
CEOGregory J. Divis Jr.
Employees188
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
IPO Date1996-06-07
10 Earlsfort Terrace
Dublin 2
IE
Dublin 2
IE
353 1 901 5201
About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc is a biopharmaceutical firm primarily conducting its operations within the United States. The company's flagship investigational drug, FT218, a specialized compound of sodium oxybate, is currently in Phase 3 clinical trials. This therapeutic candidate aims to alleviate severe daytime somnolence and sudden muscle weakness (cataplexy) in adult individuals afflicted with narcolepsy. Established in 2015, the entity was formerly recognized as Flamel Technologies SA before rebranding as Avadel Pharmaceuticals plc in January 2017. Its global headquarters are situated in Dublin, Ireland.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Weiss Asset Manageme | S-Sale | 11,112,052 | $21.00 | 2026-02-13 |
| Rodriguez Susan | D-Return | 300,000 | $9.59 | 2026-02-12 |
| Thornton Peter J. | D-Return | 42,000 | $8.07 | 2026-02-12 |
| Thornton Peter J. | D-Return | 42,000 | $4.79 | 2026-02-12 |
| Thornton Peter J. | D-Return | 11,000 | $10.83 | 2026-02-12 |